ACR Meeting Abstracts

ACR Meeting Abstracts

  • Home
  • Meetings Archive
    • ACR Convergence 2022
    • ACR Convergence 2021
    • ACR Convergence 2020
    • 2020 ACR/ARP PRSYM
    • 2019 ACR/ARP Annual Meeting
    • 2018 ACR/ARHP Annual Meeting
    • 2017-2009 Meetings
    • Download Abstracts
  • Keyword Index
  • Advanced Search
  • Your Favorites
    • Favorites
    • Login
    • View and print all favorites
    • Clear all your favorites
  • Meeting Resource Center

Abstract Number: 1637

Serious Infections Among Psoriatic Arthritis Patients Taking TNF Inhibitors Versus Non-TNF Biologics: A Systematic Review and Network Meta-Analysis

Saad Ullah Malik1, Kinza Muzaffar2, Jawad Bilal3, Warda Faridi4 and Salman Muddassir5, 1University of Arizona, Tucson, AZ, 2Internal medicine, Oak Hill Hospital,affiliated with USF, spring hill, FL, 3Internal Medicine, University of Arizona, Tucson, AZ, 4Department of Hematology/Oncology, University of Arizona, Tucson, AZ, 5Oakhill Hospital, Brookesville, FL

Meeting: 2018 ACR/ARHP Annual Meeting

Keywords: Psoriatic arthritis

  • Tweet
  • Email
  • Print
Session Information

Date: Monday, October 22, 2018

Session Title: Spondyloarthritis Including Psoriatic Arthritis – Clinical Poster II: Clinical/Epidemiology Studies

Session Type: ACR Poster Session B

Session Time: 9:00AM-11:00AM

Background/Purpose:

Psoriatic arthritis (PsA) is an inflammatory condition of peripheral joints. If left untreated, it can lead to significant pain and joint deformity. Its treatment has undergone a revolution with the advent of TNF inhibitors and non-TNF biologics. Generally, these agents are well tolerated but due to their immunosuppressive properties there has been concerns for the increased risk of infections. The aim of this study was to estimate the risk of serious infections among patients with active PsA who are receiving either TNF inhibitors or non-TNF biologics.

Methods:

We conducted a systematic review and random-effects network meta-analysis of randomized clinical trials in STATA 15.1 assessing the occurrence of serious infections with the use of TNF inhibitors (etanercept, adalimumab, infliximab, certolizumab pegol, golimumab) and non-TNF biologics (apremilast, secukinumab, ixekizumab, brodalumab, ustekinumab, abatacept, tofacitinib, guselkumab, rituximab, tildrakizumab) in adult patients with PsA. We used random effects model to estimate the pooled odds ratios (ORs) and 95% confidence interval (CI). Serious infections in included trials were defined as those requiring hospitalization or discontinuation of therapy. Studies from five databases: PubMed, EMBASE, Cochrane, Web of Science and Clinicaltrials.gov databases were included from date of inception to June 4, 2018. The risk of bias of each study was evaluated using Grading of Recommendations Assessment, Development and Evaluation (GRADE) tool for clinical trials.

Results:

2,052 citations were identified and on reviewing full-text papers 16 randomized clinical trials (n=4705) met our inclusion criteria. Based on 12 to 24-week placebo-controlled follow-up data, we identified seven trials using TNF inhibitors (infliximab, adalimumab, certolizumab and golimumab) and 9 trials using non-TNF biologics (apremilast, secukinumab, ixekizumab, bordalumab, ustekinumab, abatacept, tofacitinib). There was no statistically significant difference in odds ratio of serious infection between TNF inhibitors and non-TNF biologics. Overall, ustekinomab had lowest odds of serious infections (0.17, 95% CI: 0.01-4.1) followed by golimumab (0.23 95% CI: 0.06-0.92) and apremilast (0.50, 95% CI:0.07-3.50). Highest rate of serious infection was observed with inflixmab (OR 2.95, 95% CI:0.30-28.16).

Conclusion:

TNF inhibitors were not found to confer a higher risk of serious infection than non-TNF biologics. These results provide a better understanding of the risk of serious infection from psoriatic arthritis pharmacotherapy in patients.


Disclosure: S. U. Malik, None; K. Muzaffar, None; J. Bilal, None; W. Faridi, None; S. Muddassir, None.

To cite this abstract in AMA style:

Malik SU, Muzaffar K, Bilal J, Faridi W, Muddassir S. Serious Infections Among Psoriatic Arthritis Patients Taking TNF Inhibitors Versus Non-TNF Biologics: A Systematic Review and Network Meta-Analysis [abstract]. Arthritis Rheumatol. 2018; 70 (suppl 9). https://acrabstracts.org/abstract/serious-infections-among-psoriatic-arthritis-patients-taking-tnf-inhibitors-versus-non-tnf-biologics-a-systematic-review-and-network-meta-analysis/. Accessed January 30, 2023.
  • Tweet
  • Email
  • Print

« Back to 2018 ACR/ARHP Annual Meeting

ACR Meeting Abstracts - https://acrabstracts.org/abstract/serious-infections-among-psoriatic-arthritis-patients-taking-tnf-inhibitors-versus-non-tnf-biologics-a-systematic-review-and-network-meta-analysis/

Advanced Search

Your Favorites

You can save and print a list of your favorite abstracts during your browser session by clicking the “Favorite” button at the bottom of any abstract. View your favorites »

ACR Pediatric Rheumatology Symposium 2020

© COPYRIGHT 2023 AMERICAN COLLEGE OF RHEUMATOLOGY

Wiley

  • Home
  • Meetings Archive
  • Advanced Search
  • Meeting Resource Center
  • Online Journal
  • Privacy Policy
  • Permissions Policies
  • Cookie Preferences